18 and older, female only, with Metastatic Breast Cancer or Brain Metastases. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percent of Participants With Central Nervous System (CNS) Progression Free Survival (PFS)Primary· At 12 weeks
The study team will assess the percent of participants without CNS progression at 3 months. The study team will generate a Kaplan- Meier curve of CNS PFS and estimate the PFS and 95% confidence interval (CI) of the PFS. Response and progression by MR were evaluated using WHO/modified McDonald's criteria.
Group
Value
95% CI
Eribulin Mesylate
88.9
51 – 99.7
Objective Response Rate (RR)Secondary· up to 2 years from start of treatment
The study team will calculate the percent of participants with complete and partial response. Response and progression by MR were evaluated using WHO/modified McDonald's criteria.
Group
Value
95% CI
Eribulin Mesylate
11.1
Median Duration of CNS ResponseSecondary· up to 2 years from start of treatment
The study team will calculate the duration of CNS response. Response and progression by MR were evaluated using WHO/modified McDonald's criteria.
Group
Value
95% CI
Eribulin Mesylate
22.6
4.3 – 31.9
Number of Patients Treated With Eribulin Who Experienced Serious Adverse EventsSecondary· up to 2 years from start of treatment
The study team will evaluate rates (and 95% CI) of toxicity in patients treated with eribulin.
Group
Value
95% CI
Eribulin Mesylate
3
Number of Patients With CBRSecondary· At 12 weeks
The study team will sum the proportion of the patients with complete response, partial response and stable disease at 12 weeks (CBR)
Group
Value
95% CI
Eribulin Mesylate
5
Median Overall Survival (OS)Secondary· up to 2 years from start of treatment
The study team will generate a Kaplan-Meier curve of OS.
Group
Value
95% CI
Eribulin Mesylate
15.7
4.0 – 27.3
Adverse events — posted to ClinicalTrials.gov
Time frame: 30 days after treatment has been discontinued, an average of 5 months.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Subjects are asked to take part in a clinical research study that tests Eribulin, a new drug. Eribulin is an investigational (experimental) anti-cancer agent that has not been approved by the Food and Drug Administration (FDA) for use in patients with brain metastases. Eribulin is FDA approved for use in patients with metastatic breast cancer but the effect it may or may not have on brain metastases has not been studied.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06590558 — Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Er
· Phase 1
· withdrawn
NCT05041101 — Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
· Phase 1, PHASE2
· terminated
NCT04579224 — Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothel
· Phase 3
· active not recruiting
NCT04345913 — Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
· Phase 1, PHASE2
· active not recruiting
NCT05206656 — Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer
· Phase 2
· completed
Other recruiting trials for Metastatic Breast Cancer
Currently open trials in the same condition.
NCT07524855 — A Study of HLD-0117 in Patients With Metastatic Breast Cancer
· Phase 1
· recruiting
NCT07408089 — Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
· Phase 1
· recruiting
NCT07233928 — Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Canc
· NA
· recruiting
NCT07347600 — A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated,
· recruiting
Other Case Comprehensive Cancer Center trials
Trials by the same sponsor.
NCT06811454 — Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)
· NA
· not yet recruiting
NCT07167056 — Artificial Intelligence-Powered Support For Quality Of Life Improvement In Participants With Cancer
· NA
· recruiting
NCT07084779 — Investigation of Impact of AI on Prostate Cancer Workflow
· NA
· recruiting
NCT06904482 — Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
· Phase 2
· recruiting
NCT07044362 — Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Case Comprehensive Cancer Center
Last refreshed: 30 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02581839.